We can only compete in the marketplace with products authorized by the FDA. And we can only communicate reduced harm information if the FDA permits.
That's why we are seeking authorization from the FDA to put truthful, accurate information about reduced-risk products in the hands of consumers so that they can make a choice that's right for them. To date, we have:
- Supported Philip Morris International (PMI) on its Modified Risk Tobacco Product application (MRTPA) application for IQOS tobacco heating system. Philip Morris USA has an exclusive agreement with PMI to commercialize IQOS in the United States. On July 7, 2020, FDA authorized the marketing of the IQOS as a modified risk tobacco product with a reduced exposure claim.
- Submitted MRTPA for Copenhagen Snuff.
We believe it is critically important that the FDA take steps to foster the innovation of potentially reduced risk products. For tobacco harm reduction to be successful, a marketplace of FDA-authorized reduced-risk products must be in place, with more information about the relative risks of those products being communicated to adult smokers. The regulatory system should respect the rights of adults to make decisions based on accurate information. To make this a reality, the FDA needs to establish clear foundational rules for bringing these new innovative products to market.